Conjugate of anti-human DLL4 humanized antibody and maytansine alkaloid DM1, preparation method and application thereof
The invention relates to the technical field of biopharmacy, discloses a conjugate of an anti-human DLL4 (Delta like 4) humanized antibody and maytansine alkaloid DM1, a preparation method and application thereof. A coupled conjugate of the novel anti-human DLL4 humanized antibody THL4 and the mayta...
Gespeichert in:
Hauptverfasser: | , , , , , , , |
---|---|
Format: | Patent |
Sprache: | chi ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The invention relates to the technical field of biopharmacy, discloses a conjugate of an anti-human DLL4 (Delta like 4) humanized antibody and maytansine alkaloid DM1, a preparation method and application thereof. A coupled conjugate of the novel anti-human DLL4 humanized antibody THL4 and the maytansine alkaloid DM1 is obtained. The preparation method and the application are characterized in thatthe small molecular toxin maytansine alkaloid DM1 is coupled to an engineered anti-human DLL4 humanized antibody THL4 in a fixed-point manner to synthesize the conjugate. The conjugate HLmD4 is usedfor promoting the tumor targeting of toxin molecule DM1, reducing the toxic action on normal cells of a body and achieving a better treatment effect.
本发明公开抗人DLL4人源化抗体与美登素生物碱DM1的偶联物及其制备方法与应用,获得的新抗人DLL4人源化抗体THL4与美登素生物碱DM1的偶联结合物,涉及生物制药技术领域。其特征在于:小分子毒素美登素生物碱DM1定点偶联在工程化抗人DLL4人源化抗体THL4上合成偶联物的制备方法及用途。所述的偶联物HLmD4在于促进毒素分子DM1的肿瘤靶向性,减少对机体正常细胞的毒害作用,达到更好的治疗效果。 |
---|